Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms
Dementia is a syndrome of global and progressive deterioration of cognitive skills, especially memory, learning, abstract thinking, and orientation, usually affecting the elderly. The most common forms are Alzheimer’s disease, vascular dementia, and other (frontotemporal, Lewy body disease) dementia...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Genes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4425/14/11/2048 |
| _version_ | 1797459231460294656 |
|---|---|
| author | Barbara Vuic Tina Milos Lucija Tudor Matea Nikolac Perkovic Marcela Konjevod Gordana Nedic Erjavec Vladimir Farkas Suzana Uzun Ninoslav Mimica Dubravka Svob Strac |
| author_facet | Barbara Vuic Tina Milos Lucija Tudor Matea Nikolac Perkovic Marcela Konjevod Gordana Nedic Erjavec Vladimir Farkas Suzana Uzun Ninoslav Mimica Dubravka Svob Strac |
| author_sort | Barbara Vuic |
| collection | DOAJ |
| description | Dementia is a syndrome of global and progressive deterioration of cognitive skills, especially memory, learning, abstract thinking, and orientation, usually affecting the elderly. The most common forms are Alzheimer’s disease, vascular dementia, and other (frontotemporal, Lewy body disease) dementias. The etiology of these multifactorial disorders involves complex interactions of various environmental and (epi)genetic factors and requires multiple forms of pharmacological intervention, including anti-dementia drugs for cognitive impairment, antidepressants, antipsychotics, anxiolytics and sedatives for behavioral and psychological symptoms of dementia, and other drugs for comorbid disorders. The pharmacotherapy of dementia patients has been characterized by a significant interindividual variability in drug response and the development of adverse drug effects. The therapeutic response to currently available drugs is partially effective in only some individuals, with side effects, drug interactions, intolerance, and non-compliance occurring in the majority of dementia patients. Therefore, understanding the genetic basis of a patient’s response to pharmacotherapy might help clinicians select the most effective treatment for dementia while minimizing the likelihood of adverse reactions and drug interactions. Recent advances in pharmacogenomics may contribute to the individualization and optimization of dementia pharmacotherapy by increasing its efficacy and safety via a prediction of clinical outcomes. Thus, it can significantly improve the quality of life in dementia patients. |
| first_indexed | 2024-03-09T16:48:28Z |
| format | Article |
| id | doaj.art-ff3b71baaf794175ae9437496604810a |
| institution | Directory Open Access Journal |
| issn | 2073-4425 |
| language | English |
| last_indexed | 2024-03-09T16:48:28Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Genes |
| spelling | doaj.art-ff3b71baaf794175ae9437496604810a2023-11-24T14:43:57ZengMDPI AGGenes2073-44252023-11-011411204810.3390/genes14112048Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric SymptomsBarbara Vuic0Tina Milos1Lucija Tudor2Matea Nikolac Perkovic3Marcela Konjevod4Gordana Nedic Erjavec5Vladimir Farkas6Suzana Uzun7Ninoslav Mimica8Dubravka Svob Strac9Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, CroatiaLaboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, CroatiaLaboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, CroatiaLaboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, CroatiaLaboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, CroatiaLaboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, CroatiaLaboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, CroatiaDepartment for Biological Psychiatry and Psychogeriatry, University Hospital Vrapce, 10000 Zagreb, CroatiaDepartment for Biological Psychiatry and Psychogeriatry, University Hospital Vrapce, 10000 Zagreb, CroatiaLaboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, CroatiaDementia is a syndrome of global and progressive deterioration of cognitive skills, especially memory, learning, abstract thinking, and orientation, usually affecting the elderly. The most common forms are Alzheimer’s disease, vascular dementia, and other (frontotemporal, Lewy body disease) dementias. The etiology of these multifactorial disorders involves complex interactions of various environmental and (epi)genetic factors and requires multiple forms of pharmacological intervention, including anti-dementia drugs for cognitive impairment, antidepressants, antipsychotics, anxiolytics and sedatives for behavioral and psychological symptoms of dementia, and other drugs for comorbid disorders. The pharmacotherapy of dementia patients has been characterized by a significant interindividual variability in drug response and the development of adverse drug effects. The therapeutic response to currently available drugs is partially effective in only some individuals, with side effects, drug interactions, intolerance, and non-compliance occurring in the majority of dementia patients. Therefore, understanding the genetic basis of a patient’s response to pharmacotherapy might help clinicians select the most effective treatment for dementia while minimizing the likelihood of adverse reactions and drug interactions. Recent advances in pharmacogenomics may contribute to the individualization and optimization of dementia pharmacotherapy by increasing its efficacy and safety via a prediction of clinical outcomes. Thus, it can significantly improve the quality of life in dementia patients.https://www.mdpi.com/2073-4425/14/11/2048dementiageneticspharmacogenomicscognitive impairmentneuropsychiatric symptomsdrug response |
| spellingShingle | Barbara Vuic Tina Milos Lucija Tudor Matea Nikolac Perkovic Marcela Konjevod Gordana Nedic Erjavec Vladimir Farkas Suzana Uzun Ninoslav Mimica Dubravka Svob Strac Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms Genes dementia genetics pharmacogenomics cognitive impairment neuropsychiatric symptoms drug response |
| title | Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms |
| title_full | Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms |
| title_fullStr | Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms |
| title_full_unstemmed | Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms |
| title_short | Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms |
| title_sort | pharmacogenomics of dementia personalizing the treatment of cognitive and neuropsychiatric symptoms |
| topic | dementia genetics pharmacogenomics cognitive impairment neuropsychiatric symptoms drug response |
| url | https://www.mdpi.com/2073-4425/14/11/2048 |
| work_keys_str_mv | AT barbaravuic pharmacogenomicsofdementiapersonalizingthetreatmentofcognitiveandneuropsychiatricsymptoms AT tinamilos pharmacogenomicsofdementiapersonalizingthetreatmentofcognitiveandneuropsychiatricsymptoms AT lucijatudor pharmacogenomicsofdementiapersonalizingthetreatmentofcognitiveandneuropsychiatricsymptoms AT mateanikolacperkovic pharmacogenomicsofdementiapersonalizingthetreatmentofcognitiveandneuropsychiatricsymptoms AT marcelakonjevod pharmacogenomicsofdementiapersonalizingthetreatmentofcognitiveandneuropsychiatricsymptoms AT gordananedicerjavec pharmacogenomicsofdementiapersonalizingthetreatmentofcognitiveandneuropsychiatricsymptoms AT vladimirfarkas pharmacogenomicsofdementiapersonalizingthetreatmentofcognitiveandneuropsychiatricsymptoms AT suzanauzun pharmacogenomicsofdementiapersonalizingthetreatmentofcognitiveandneuropsychiatricsymptoms AT ninoslavmimica pharmacogenomicsofdementiapersonalizingthetreatmentofcognitiveandneuropsychiatricsymptoms AT dubravkasvobstrac pharmacogenomicsofdementiapersonalizingthetreatmentofcognitiveandneuropsychiatricsymptoms |